Accuprec Research Labs, Walk In Interview for Freshers on 18th Dec’21

Accuprec Research Labs, Walk In Interview for Freshers & Experience B.Pharm / M.Pharm / Any Graduate in QA / Regulatory Affairs / DCO / Store / Archivist on 18th Dec’21

Departments: QA / Regulatory Affairs / DCO / Store / ArchivistDesignation: Officer / Executive

Designation: Officer / Executive

Experience: 0 to 2 yrsQualification: B.Pharm / M.Pharm / Any Graduate

Qualification: B.Pharm / M.Pharm / Any GraduateInterview Mode: Walk-In Interview

Interview Mode: Walk-In InterviewJob Location: Ahmedabad

Job Location: Ahmedabad

Interview Date : 18th Dec’21

Time : 10:00 AM to 04:00 PM

𝐕𝐞𝐧𝐮𝐞:

𝐀𝐜𝐜𝐮𝐩𝐫𝐞𝐜 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐋𝐚𝐛𝐬 𝐏𝐯𝐭. 𝐋𝐭𝐝.

𝐎𝐩𝐩. 𝐙𝐲𝐝𝐮𝐬 𝐏𝐡𝐚𝐫𝐦𝐞𝐳,

𝐂𝐡𝐚𝐧𝐠𝐨𝐝𝐚𝐫 – 𝐁𝐚𝐯𝐥𝐚 𝐇𝐢𝐠𝐡𝐰𝐚𝐲,

𝐍𝐫. 𝐌𝐚𝐭𝐨𝐝𝐚 𝐏𝐚𝐭𝐢𝐲𝐚,

𝐀𝐡𝐦𝐞𝐝𝐚𝐛𝐚𝐝,

𝐆𝐮𝐣𝐚𝐫𝐚𝐭 𝟑𝟖𝟐𝟐𝟏𝟑

𝐖𝐨𝐫𝐤 𝐋𝐨𝐜𝐚𝐭𝐢𝐨𝐧: 𝐀𝐡𝐦𝐞𝐝𝐚𝐛𝐚𝐝

• Granules India Walk-In Interview on 14 May 2025 for API Production & SRS Roles
  Granules India Limited is a leading Indian multinational pharmaceutical company headquartered in Hyderabad, Telangana. Established in 1984 as Triton Laboratories, the company initially focused on producing Paracetamol API. In 1991, it was rebranded as Granules India Limited and has since evolved… Read more: Granules India Walk-In Interview on 14 May 2025 for API Production & SRS Roles
• FDA approves nivolumab with ipilimumab for unresectable or metastatic MSI-H or dMMR colorectal cancer
  The Food and Drug Administration approved nivolumab (Opdivo, Bristol Myers Squibb Company) with ipilimumab (Yervoy, Bristol Myers Squibb Company) for adult and pediatric patients 12 years of age and older with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient… Read more: FDA approves nivolumab with ipilimumab for unresectable or metastatic MSI-H or dMMR colorectal cancer
• Glenmark receives ANDA approval for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% (OTC)
  Glenmark Pharmaceuticals Inc., USA (Glenmark) has received final approval by the United States Food & Drug Administration (U.S. FDA) for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% (OTC), determined by the FDA to be bioequivalent1to Pataday®2 Once Daily Relief Ophthalmic Solution, 0.2%… Read more: Glenmark receives ANDA approval for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% (OTC)
• FDA Announces Expanded Use of Unannounced Inspections at Foreign Manufacturing Facilities
  The U.S. Food and Drug Administration announced its intent to expand the use of unannounced inspections at foreign manufacturing facilities that produce foods, essential medicines, and other medical products intended for American consumers and patients. This change builds upon the agency’s… Read more: FDA Announces Expanded Use of Unannounced Inspections at Foreign Manufacturing Facilities
• Vital Therapeutics Freshers & Experts walk in for RO/DM Plant Operators, & Production Chemists | 10th May
  Based in Hyderabad, Telangana, Vital Therapeutics & Formulations Pvt. Ltd. is a pharmaceutical manufacturing company established in 2004. With over 25 years of expertiseContentsRequirement Details:Walk in interview details: Vital Therapeutics and Formulations – Walk in Interviews for RO, DM Plant Operator… Read more: Vital Therapeutics Freshers & Experts walk in for RO/DM Plant Operators, & Production Chemists | 10th May